BT Group, which virtually owns the UK telecommunications market, isn't waiting for Google (GOOG) to launch a full attack. The company probably expects to be under assault from the search engine (and advertising and e-mail) giant, so it's taking early action. Google Voice is still being tested, but words like "free" and "powerful" and "internet-based" are bound to inspire fear in even the most established of companies.

To protect itself from the eventual attack from Mountain View, BT picked up Ribbit Mobile, and testing is in progress. Ribbit's technology has some overlap with Google Voice and even beats it with a few capabilities, according to Bloomberg. Ribbit just launched its beta product this month. It allows either the user's current phone number or a new one from Ribbit -- which is no different from Google's alternative. The product suite is generally the same, with phone- and web-based voicemail retrieval and automatic transcriptions that can be sent by text message or e-mail. For an extra fee, BT's Ribbit does provide human transcription, though it is free during testing. And, calls can be taken directly from a computer, using a microphone and speakers.

Analyst upgrades:

• Morgan Keegan upgraded Motorola (NYSE: MOT) to Outperform from Market Perform due to the increased visibility of Android-based launches, as well as the stock's valuation.
• OfficeMax (NYSE: OMX) was upgraded to Buy from Hold by Citigroup, which cited the company's stabilizing sales trend, accelerating share gains, and valuation.
• Kaufman Bros. upgraded iRobot (NASDAQ: IRBT) to Buy from Hold on valuation.
• Cancaccord upgraded Rio Tinto (NYSE: RTP) to Buy from Hold citing the turnaround in the aluminum business and its exposure to copper.
• Wells Fargo upgraded Smith & Nephew (NYSE: SNN) to Market Perform from Underperform.
• BT Group (NYSE: BT) was upgraded to Neutral from Reduce by Nomura.
• Societe Generale raised L'Oreal (OTC: LRLCY) to Buy from Sell.
• Franklin Resources (NYSE: BEN) was upgraded to Buy from Hold by Sandler O'Neill.

Analyst upgrades:

• Canaccord upgraded Imperial Oil (NYSE: IMO) to Buy from Speculative Buy following an increase in crude oil forecast.
• BT Group (NYSE: BT) was upgraded to Outperform from Market Perform at Bernstein.
  
• Novartis (NYSE: NVS) was upgraded to Overweight from Neutral at JP Morgan.
  
• CommVault (NASDAQ: CVLT) was upgraded to Neutral from Sell at Goldman.
  
• AvalonBay (NYSE: AVB) was upgraded to Buy from Hold at Sandler O'Neill.

Analyst upgrades:

• Baird upgraded URS Corp. (NYSE: URS) to Outperform from Neutral and raised its target to Outperform from Neutral based on momentum of new wins from stimulus funds and expectations for additional nuclear contracts.
• Jefferies upgraded EnerSys (NYSE: ENS) to Buy from Hold following the recent share weakness as it believes volumes have stopped declining and the June quarter is likely the bottom. The firm raised its target price to $18 from $11.
• RBC Capital upgraded Camden Property (NYSE: CPT) to Outperform from Sector Perform citing the company's improved financial capacity and portfolio position. The firm raised its target price to $34 from $23.
• CBS Corp (NYSE: CBS) was upgraded to Equal Weight from Underweight at Barclays.
• UDR (NYSE: UDR) was raised to Sector Perform from Underperform at RBC Capital and to Outperform from Market Perform at Keefe Bruyette.
• Zale (NYSE: ZLC) was upgraded to Buy from Neutral at BofA/Merril.

Analyst upgrades:

• Deutsche Bank upgraded BT Group (NYSE: BT) to Buy from Hold as it believes the company's Q4 results could remove uncertainty and cost cutting initiatives could drive upside.
  
• Baird upgraded Stanley Works (NYSE: SWK) to Outperform from Neutral and raised their target to $42 from $34 citing valuation, solid execution, and growth potential.
  
• Citigroup upgraded Netflix (NASDAQ: NFLX) to Buy from Hold as it believes the recent sell-off presents an attractive buying opportunity. The firm believes Netflix has one of the best earnings outlooks in the internet sector and increased its target price to $52 from $37.
• AstraZeneca (NASDAQ: AZN) was upgraded to Buy from Neutral at UBS.
  
• Joy Global (NYSE: JOYG) and Bucyrus (NYSE: BUCY) were raised to Buy from Neutral at Goldman.

Analyst upgrades:

• Merriman upgraded Taser (NASDAQ: TASR) to Buy from Neutral as it believes current valuation levels do not reflect the company's market opportunities and that the law enforcement funding in President Obama's stimulus plan will boost sales in Q4 and FY10.
  
• Goldman upgraded Macy's (NYSE: M) to Buy from Neutral and added shares to its Conviction Buy List based on reduced balance sheet concerns and improved risk/reward. The firm also raised their target to $8.25 from $8.
  
• JP Morgan upgraded Family Dollar (NYSE: FDO) to Neutral from Underweight and raised its target to $29 from $19 following the better-than-expected Q2 report. The analyst continues to prefer Dollar Tree (NASDAQ: DLTR) and Wal-Mart (NYSE: WMT).
• Goldman removed Universal Am (NYSE: UAM) from the Conviction Sell List.
  
• McDermott (NYSE: MDR) was upgraded to Buy from Hold at Jefferies.
  
• Canadian Natural (NYSE: CNQ) was upgraded to Sector Outperformer from Sector Performer at CIBC.

I am the Global Editor at MoneyShow.com and each week I interview an investing expert. This week, I spoke with Chris Gilchrist, editorial director of EveryInvestor, who tells investors how they should protect themselves, diversify, and position their portfolios for a rebound.

Q. Chris, in an interview at the recent World Money Show in London, you discussed the failure of the most widely used diversification strategies during the current global market declines. Why did it happen?

A. There are two major reasons. First, current portfolio planning techniques are based on portfolio theory, which systematically underestimates the frequency of extreme events as well as the size of potential losses. 'Standard deviation' is a false measure of risk because investment returns are not 'normally distributed'. Inadequate recognition of risk meant advisers recommended too high a proportion of capital be invested in equities.

Second, finance theorists hold that the excess annual return on equities above risk-free bonds should be no more than 2% to 3% as against a historical 5% to 7%, but this, too, is contrary to what we know about investors. It assumes investors are indifferent between loss and gain, when we know investors are about twice as risk-averse as they are gain-seeking and that this systematically skews their behavior.

Nevertheless, if you follow the theory, you end up putting more capital into risky assets in order to achieve your target rate of return. So, the failure arose not from diversification itself-though that, too, has been problematic-but from putting too high a proportion of assets into riskier assets.

Analyst upgrades:

• Goldman upgraded Baidu (NASDAQ: BIDU) to Buy from Neutral and added shares to its Conviction Buy List. The analyst expects Baidu to benefit from growth in paid search in China, where growth is expected to be 30% annually.
  
• Friedman Billings upgraded shares of Corporate Office Properties (NYSE: OFC) to Outperform from Market Perform to reflect the company's exposure to the "sound" Washington, D.C., market and "favorable" liquidity position.
  
• Soleil upgraded Sunoco (NYSE: SUN) to Buy from Hold and raised its target to $45 from $38 on the strength of the company's non-refining segment.
• Mosaic (NYSE: MOS), Potash (NYSE: POT), Intrepid Potash (NYSE: IPI) and Terra Industries (NYSE: TRA) were upgraded to Buy from Neutral at Merrill Lynch.
  
• Kroger (NYSE: KR) was upgraded to Neutral from Underweight at JP Morgan.

Analyst downgrades:

• Jefferies downgraded shares of Bronco Drilling (NASDAQ: BRNC) to Underperform from Hold and lowered its target to $4.50 from $7.50 on valuation and their expectations for a rig decline in U.S. drilling activity.
  
• Morgan Stanley cut Credit Suisse (NYSE: CS) to Equal Weight from Overweight into reporting season on concerns of further impairment charges.
  
• Deutsche Bank downgraded Ericsson (NASDAQ: ERIC) to Sell from Hold to reflect challenges in the handset market.
• Alcatel-Lucent (NYSE: ALU) was lowered to Sell from Hold at WestLB.
  
• BT Group (NYSE: BT) was slashed at JP Morgan to Underweight from Neutral.
  
• Sovereign Bancorp (NYSE: SOV) was downgraded to Market Perform from Outperform at Keefe Bruyette.

Analyst initiations:

Analyst upgrades:

• UBS upgraded Safeway (NYSE:SWY) to Buy from Neutral based on valuation.
  
• AthroCare (NASDAQ:ARTC) was raised to Neutral from Negative at Susquehanna on valuation.
• BT Group (NYSE:BT) was raised to Neutral from Underperform at Credit Suisse.
  
• Leap Wireless (NASDAQ:LEAP) was upgraded at Goldman to Buy from Neutral.
  
• China Mobile (NYSE:CHL) was upgraded to Buy from Neutral at Merrill Lynch.

Analyst downgrades:

• Jefferies downgraded shares of Albany Molecular (NASDAQ:AMRI) to Underperform from Hold on concerns regarding the company's exposure to small biopharma as their checks suggest biopharmaceutical companies that rely on the capital markets to fund operations are cutting back significantly on R&D projects. The firm lowered their target to $8 from $10.
• Baird downgraded Sirona Dental (NASDAQ:SIRO) to Neutral from Outperform and lowered their target to $15 from $21 due to lack of catalysts and better options in dental.
  
• Stephens cut Hub Group (NASDAQ:HUBG) to Equal Weight from Overweight on the expectation that weaker volumes will lead to pricing pressure. The firm lowered their target to $24 from $36.
• Teco Energy (NYSE:TE) was downgraded to Hold from Buy at KeyBanc.
  
• RF Micro Devices (NASDAQ:RFMD) was lowered to Underperform from Buy at Merrill Lynch.
  
• Energy Conversion (NASDAQ:ENER) was cut to Underweight from Equal Weight at Barclays.

Analyst upgrades:

• Stephens upgraded shares of Ann Taylor (NYSE: ANN) to Overweight from Equal Weight to reflect the company's restructuring program, reductions in inventory and share repurchase program.
  
• AIMCO (NYSE: AIV) was upgraded to Buy from Hold at Deutsche Bank.
  
• UBS upgraded D.R. Horton (NYSE: DHI) to Neutral from Sell.
• Argus believes BigBand Networks (NASDAQ: BBND) is succeeding by adding new customers and driving new business with existing customers. Shares were upgraded to Buy from Hold.
  
• ThinkPanmure expects Capella Education (NASDAQ: CPLA) to attract students at a faster rate in the coming quarters and to improve operating margins. The firm raised shares to Buy from Accumulate and raised its target to $60 from $62.
• Advanced Medical (NYSE:EYE) was lifted to Hold from Underperform at Jefferies.

Analyst downgrades:

This week BT PLC (formerly British Telecommunications PLC) (NYSE: BT) got lots of favorable coverage for relenting on its plan to remove thousands of iconic red phone boxes. BT announced in June it wanted to replace about one-third of its remaining 12,000 red phone boxes. The company has slowly been dispatching the boxes for years, prompting small local protests all along and a big outcry this summer.

BT proposed a new deal: for £1 a town could keep the box, but with no working phone. A working phone would cost £500 ($900) a year. According to The Telecom, BT says £500 ($900) pounds is only half the annual cost of operating a red phone box. Really, $1,800 a year to maintain a pay phone? This July, residents in Cornwall were told their phone, which had been broken since June, wouldn't be fixed till late August. In protest, they strung up a bunch of tin cans on strings inside the booth.

Analyst upgrades:

• Goldman upgraded BT Group (NYSE: BT) to Buy from Neutral on valuation and improved earnings visibility.
  
• Soleil upgraded shares of Jo Ann Stores (NYSE: JAS) to Buy from Hold following the company's Q2 upside surprise to reflect strong fundamentals and market share gains. The firm raised Jo Ann's target to $30 from $25.
  
• Amylin Pharma (NASDAQ: AMLN) was upgraded to Buy from Neutral at Merrill Lynch.
  
• Energen (NYSE: EGN) was upgraded to Buy from Neutral at UBS.

Analyst downgrades:

• Roth Capital downgraded shares of Warner Chilcott (NASDAQ: WCRX) to Hold from Buy pending patent clarity for the company's lead drug, Loestrin 24 for birth control. The firm lowered their target to $18 from $20.
• JP Morgan cut China Mobile (NYSE: CHL) to Underweight from Overweight as they believe increased competition may limit earnings growth.
  
• Cantor downgraded shares of Cell Genesys (NASDAQ: CEGE) to Hold from Buy following the termination of the VITAL-2 Phase III clinical trial. The firm also lowered their target to $2 from $10.
• Coca-Cola (NYSE: KO) was lowered to Neutral from Outperform at Credit Suisse.
  
• Gilead Sciences (NASDAQ: GILD) was downgraded to Equal Weight from Overweight at Lehman.
  
• Cinemark (NYSE: CNK) was downgraded at BMO Capital to Market Perform from Outperform.

MOST NOTEWORTHY: Wachovia, American International Group and BT Group were today's noteworthy downgrades:

• Oppenheimer downgraded shares of Wachovia (NYSE: WB) to Underperform from Perform as they believe the outlook is "bleak" for equity shareholders. The firm thinks Wachovia's expenses can't come down fast enough too offset earnings erosion.
  
• Wachovia downgraded shares of American International Group (NYSE: AIG) to Market Perform from Outperform as they believe AIG's CDO valuations worsened in Q2, which could result in a $2B-$7B after tax "valuation adjustment." Wachovia expects the value of AIG's core insurance franchise to be obscured by its credit exposure.
  
• Collins Stewart cut BT Group (NYSE: BT) to Hold from Buy on concerns surrounding the company's fiber network expansion.

OTHER DOWNGRADES:

• Nokia (NYSE: NOK) was downgraded to Add from Buy at WestLB; the firm also lowered Ericsson (NASDAQ: ERIC) to Hold from Buy and Alcatel-Lucent (NYSE: ALU) to Sell from Hold.
  
• Third Wave (NASDAQ: TWTI) was cut to Hold from Buy at Deutsche Bank.
  
• AT&T (NYSE: T) was removed from Goldman's Conviction Buy List.

MOST NOTEWORTHY: European banks, the Paper and Forest Products sector, Kindred Healthcare and Convergys were today's noteworthy upgrades:

• Keefe Bruyette upgraded the European Banks sector to Neutral from Underweight on valuation as they see limited downside from current levels. Included in the firm's top picks are HSBC Holdings Plc (NYSE: HBC) and Banco Santander SA (NYSE: STD).
• Credit Suisse upgraded the Paper and Forest Products sector to Overweight from Underweight citing valuations and expectations that fundamentals will bottom this fall. The firm raised shares of Temple-Inland Inc (NYSE: TIN) and Smurfit-Stone Container Corporation (NASDAQ: SSCC) to Outperform from Neutral.
• Friedman Billings upgraded shares of Kindred Healthcare Inc (NYSE: KND) to Outperform from Market Perform on valuation following the recent pullback and believes the company is well-positioned to beat modest expectations over the remainder of the year. The firm raised their target to $36 from $29.
• Oppenheimer raised Convergys Corporation (NYSE: CVG) to Outperform from Perform on valuation, as they believe investors should look at the company's business lines separately. Their sum of parts valuation yields an $18 target.

OTHER UPGRADES:

• Suncor Energy Inc (NYSE: SU) was upgraded to Overweight from Neutral at JP Morgan and to Outperform from Market Perform at Friedman Billings.
• UBS upgraded BT Group Plc (NYSE: BT) to Neutral from Sell.
• Broadcom Corporation (NASDAQ: BRCM) was upgraded to Buy from Neutral at Piper.

MOST NOTEWORTHY: Beckman Coulter, BT Group and Micromet were today's noteworthy initiations:

• Oppenheimer believes Beckman Coulter (NYSE:BEC) is well-positioned to leverage its broad installed base in the clinical lab market to increase sales of its consumable and a new molecular diagnostics instrument expected in 2010. The firm initiated shares with an Outperform rating and $80 target.
  
• Societe Generale expects BT Group's (NYSE:BT) domestic revenues to deteriorate as line erosion accelerates; shares were assumed with a Sell rating.
  
• Roth Capital started Micromet (NASDAQ:MITI) with a Buy rating and $3 target. The firm expects the company's proprietary 'BiTE' antibody platform to gain validation as its lead candidate MT103 starts accumulating clinical data in multiple hematology indications.

OTHER INITIATIONS:

• Yahoo! (NASDAQ:YHOO) was initiated with a Neutral rating at Merrill.
  
• Piper resumed coverage of Alexion Pharma (NASDAQ:ALXN) with a Buy rating and $88 target.
  
• MedAssets (NASDAQ:MDAS) was started at Jefferies with a Buy rating and $25 target.